CROs offering Phase I Clinical Trials with Cell Therapy
25 published
25 published CROs match Phase I Clinical Trials and Cell Therapy.
Locations in this set include United States, China, India, Australia, Taiwan, and United Kingdom.
Capabilities that show up most often in this set: Phase II Clinical Trials, Regulatory Affairs, Biostatistics & Statistical Programming, Clinical Operations, and Phase III Clinical Trials.
Matching companies
Syneos HealthGlobal CRO with 26,000+ employees offering integrated clinical development, regulatory affairs, and commercialization services. Helped develop or commercialize 96% of FDA-approved oncology drugs and 93% of EMA-authorized oncology products in the last five years.
Syngene InternationalInnovation-led CRDMO offering integrated scientific services from early discovery through commercial manufacturing, with cGMP-compliant facilities, 5,200+ scientists, and a new 50,000-liter single-use bioreactor capacity in the U.S.
TigermedLeading global CRO providing end-to-end clinical trial services, preclinical development, medical device and IVD trials, regulatory affairs, and real-world evidence studies across 180+ offices serving 4,000+ customers.
Worldwide Clinical TrialsFull-service global CRO with 30+ years of therapeutic expertise, delivering personalized clinical trial support across rare disease, cardiovascular, cell & gene therapy, oncology, and neuroscience.
WuXi AppTecGlobal CRDMO platform providing integrated end-to-end contract research, development, and manufacturing services across discovery, preclinical, clinical, and commercial phases for small molecules, peptides, oligonucleotides, and biologics across 30+ countries.
Markdown mirror: /explore/phase-1-clinical-trials/cell-therapy.md